Which has stronger valuation and earnings, PTGX or CDNA?

CareDx has higher revenue and earnings than Protagonist Therapeutics. CareDx is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Protagonist Therapeutics $46.02M 209.62 -$130.15M $1.03 145.63 CareDx $379.80M 6.41 -$21.35M $2.07 22.74

Does the media refer more to PTGX or CDNA?

In the previous week, Protagonist Therapeutics had 9 more articles in the media than CareDx. MarketBeat recorded 25 mentions for Protagonist Therapeutics and 16 mentions for CareDx. CareDx's average media sentiment score of 0.70 beat Protagonist Therapeutics' score of 0.53 indicating that CareDx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protagonist Therapeutics 4 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive CareDx 7 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, CDNA or SYRE?

CareDx has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CareDx $379.80M 6.41 -$21.35M $2.07 22.74 Spyre Therapeutics $890K 10,407.55 -$155.20M -$1.95 N/A

Does the media favor CDNA or SYRE?

In the previous week, Spyre Therapeutics had 8 more articles in the media than CareDx. MarketBeat recorded 24 mentions for Spyre Therapeutics and 16 mentions for CareDx. CareDx's average media sentiment score of 0.70 beat Spyre Therapeutics' score of 0.62 indicating that CareDx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CareDx 7 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spyre Therapeutics 8 Very Positive mention(s) 5 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CDNA or IONS?

In the previous week, Ionis Pharmaceuticals had 2 more articles in the media than CareDx. MarketBeat recorded 18 mentions for Ionis Pharmaceuticals and 16 mentions for CareDx. CareDx's average media sentiment score of 0.70 beat Ionis Pharmaceuticals' score of 0.19 indicating that CareDx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CareDx 7 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ionis Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to PRAX or CDNA?

In the previous week, Praxis Precision Medicines had 6 more articles in the media than CareDx. MarketBeat recorded 22 mentions for Praxis Precision Medicines and 16 mentions for CareDx. CareDx's average media sentiment score of 0.70 beat Praxis Precision Medicines' score of 0.59 indicating that CareDx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Praxis Precision Medicines 7 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive CareDx 7 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, KYMR or CDNA?

CareDx has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kymera Therapeutics $39.21M 230.26 -$311.35M -$3.24 N/A CareDx $379.80M 6.41 -$21.35M $2.07 22.74

Does the media prefer KYMR or CDNA?

In the previous week, Kymera Therapeutics had 13 more articles in the media than CareDx. MarketBeat recorded 29 mentions for Kymera Therapeutics and 16 mentions for CareDx. CareDx's average media sentiment score of 0.70 beat Kymera Therapeutics' score of -0.19 indicating that CareDx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Neutral CareDx 7 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

CareDx (CDNA) Competitors

$47.07 +0.38 (+0.81%)

As of 04:00 PM Eastern

Compare

CDNA vs. PTGX, SYRE, IONS, PRAX, and KYMR

Should you buy CareDx stock or one of its competitors? CareDx's main competitors and comparable companies include Protagonist Therapeutics (PTGX), Spyre Therapeutics (SYRE), Ionis Pharmaceuticals (IONS), Praxis Precision Medicines (PRAX), and Kymera Therapeutics (KYMR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does CareDx compare to Protagonist Therapeutics?

Protagonist Therapeutics (NASDAQ:PTGX) and CareDx (NASDAQ:CDNA) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, media sentiment, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.

Protagonist Therapeutics has a net margin of 29.40% compared to CareDx's net margin of 24.23%. Protagonist Therapeutics' return on equity of 12.03% beat CareDx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	29.40%	12.03%	11.23%
CareDx	24.23%	2.87%	2.17%

Protagonist Therapeutics currently has a consensus price target of $137.86, indicating a potential downside of 8.10%. CareDx has a consensus price target of $47.75, indicating a potential upside of 1.44%. Given CareDx's higher possible upside, analysts plainly believe CareDx is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	1 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	3.00
CareDx	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43

In the previous week, Protagonist Therapeutics had 9 more articles in the media than CareDx. MarketBeat recorded 25 mentions for Protagonist Therapeutics and 16 mentions for CareDx. CareDx's average media sentiment score of 0.70 beat Protagonist Therapeutics' score of 0.53 indicating that CareDx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	4 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
CareDx	7 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

98.6% of Protagonist Therapeutics shares are held by institutional investors. 5.2% of Protagonist Therapeutics shares are held by company insiders. Comparatively, 2.4% of CareDx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Protagonist Therapeutics has a beta of 1.78, meaning that its share price is 78% more volatile than the broader market. Comparatively, CareDx has a beta of 2.38, meaning that its share price is 138% more volatile than the broader market.

CareDx has higher revenue and earnings than Protagonist Therapeutics. CareDx is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$46.02M	209.62	-$130.15M	$1.03	145.63
CareDx	$379.80M	6.41	-$21.35M	$2.07	22.74

Summary

Protagonist Therapeutics beats CareDx on 11 of the 17 factors compared between the two stocks.

How does CareDx compare to Spyre Therapeutics?

CareDx (NASDAQ:CDNA) and Spyre Therapeutics (NASDAQ:SYRE) are both mid-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.

In the previous week, Spyre Therapeutics had 8 more articles in the media than CareDx. MarketBeat recorded 24 mentions for Spyre Therapeutics and 16 mentions for CareDx. CareDx's average media sentiment score of 0.70 beat Spyre Therapeutics' score of 0.62 indicating that CareDx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CareDx	7 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Spyre Therapeutics	8 Very Positive mention(s)	5 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

CareDx currently has a consensus target price of $47.75, suggesting a potential upside of 1.44%. Spyre Therapeutics has a consensus target price of $110.15, suggesting a potential upside of 4.58%. Given Spyre Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Spyre Therapeutics is more favorable than CareDx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CareDx	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43
Spyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87

CareDx has a net margin of 24.23% compared to Spyre Therapeutics' net margin of 0.00%. CareDx's return on equity of 2.87% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CareDx	24.23%	2.87%	2.17%
Spyre Therapeutics	N/A	-30.74%	-22.23%

CareDx has a beta of 2.38, meaning that its stock price is 138% more volatile than the broader market. Comparatively, Spyre Therapeutics has a beta of 3.03, meaning that its stock price is 203% more volatile than the broader market.

CareDx has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CareDx	$379.80M	6.41	-$21.35M	$2.07	22.74
Spyre Therapeutics	$890K	10,407.55	-$155.20M	-$1.95	N/A

80.4% of Spyre Therapeutics shares are held by institutional investors. 2.4% of CareDx shares are held by company insiders. Comparatively, 15.7% of Spyre Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

CareDx and Spyre Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does CareDx compare to Ionis Pharmaceuticals?

CareDx (NASDAQ:CDNA) and Ionis Pharmaceuticals (NASDAQ:IONS) are both mid-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

CareDx presently has a consensus price target of $47.75, suggesting a potential upside of 1.44%. Ionis Pharmaceuticals has a consensus price target of $94.65, suggesting a potential upside of 66.23%. Given Ionis Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Ionis Pharmaceuticals is more favorable than CareDx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CareDx	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43
Ionis Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	2.77

CareDx has a net margin of 24.23% compared to Ionis Pharmaceuticals' net margin of -64.76%. CareDx's return on equity of 2.87% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CareDx	24.23%	2.87%	2.17%
Ionis Pharmaceuticals	-64.76%	-111.08%	-17.41%

93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. 2.4% of CareDx shares are owned by company insiders. Comparatively, 1.8% of Ionis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

CareDx has higher earnings, but lower revenue than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CareDx	$379.80M	6.41	-$21.35M	$2.07	22.74
Ionis Pharmaceuticals	$874.09M	10.83	-$381.39M	-$3.46	N/A

In the previous week, Ionis Pharmaceuticals had 2 more articles in the media than CareDx. MarketBeat recorded 18 mentions for Ionis Pharmaceuticals and 16 mentions for CareDx. CareDx's average media sentiment score of 0.70 beat Ionis Pharmaceuticals' score of 0.19 indicating that CareDx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CareDx	7 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ionis Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

CareDx has a beta of 2.38, meaning that its share price is 138% more volatile than the broader market. Comparatively, Ionis Pharmaceuticals has a beta of 0.41, meaning that its share price is 59% less volatile than the broader market.

Summary

CareDx beats Ionis Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does CareDx compare to Praxis Precision Medicines?

Praxis Precision Medicines (NASDAQ:PRAX) and CareDx (NASDAQ:CDNA) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, media sentiment, valuation, dividends and profitability.

CareDx has a net margin of 24.23% compared to Praxis Precision Medicines' net margin of 0.00%. CareDx's return on equity of 2.87% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-34.15%	-32.42%
CareDx	24.23%	2.87%	2.17%

CareDx has higher revenue and earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	$8.55M	1,198.31	-$303.27M	-$12.93	N/A
CareDx	$379.80M	6.41	-$21.35M	$2.07	22.74

Praxis Precision Medicines has a beta of 2.78, suggesting that its stock price is 178% more volatile than the broader market. Comparatively, CareDx has a beta of 2.38, suggesting that its stock price is 138% more volatile than the broader market.

67.8% of Praxis Precision Medicines shares are held by institutional investors. 3.0% of Praxis Precision Medicines shares are held by company insiders. Comparatively, 2.4% of CareDx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Praxis Precision Medicines had 6 more articles in the media than CareDx. MarketBeat recorded 22 mentions for Praxis Precision Medicines and 16 mentions for CareDx. CareDx's average media sentiment score of 0.70 beat Praxis Precision Medicines' score of 0.59 indicating that CareDx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Praxis Precision Medicines	7 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
CareDx	7 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Praxis Precision Medicines currently has a consensus price target of $573.05, suggesting a potential upside of 56.16%. CareDx has a consensus price target of $47.75, suggesting a potential upside of 1.44%. Given Praxis Precision Medicines' stronger consensus rating and higher probable upside, equities analysts clearly believe Praxis Precision Medicines is more favorable than CareDx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	4 Strong Buy rating(s)	3.00
CareDx	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43

Summary

Praxis Precision Medicines beats CareDx on 9 of the 17 factors compared between the two stocks.

How does CareDx compare to Kymera Therapeutics?

Kymera Therapeutics (NASDAQ:KYMR) and CareDx (NASDAQ:CDNA) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations, institutional ownership and media sentiment.

Kymera Therapeutics currently has a consensus price target of $125.65, indicating a potential upside of 15.72%. CareDx has a consensus price target of $47.75, indicating a potential upside of 1.44%. Given Kymera Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Kymera Therapeutics is more favorable than CareDx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83
CareDx	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43

Kymera Therapeutics has a beta of 1.95, suggesting that its share price is 95% more volatile than the broader market. Comparatively, CareDx has a beta of 2.38, suggesting that its share price is 138% more volatile than the broader market.

In the previous week, Kymera Therapeutics had 13 more articles in the media than CareDx. MarketBeat recorded 29 mentions for Kymera Therapeutics and 16 mentions for CareDx. CareDx's average media sentiment score of 0.70 beat Kymera Therapeutics' score of -0.19 indicating that CareDx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Neutral
CareDx	7 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CareDx has a net margin of 24.23% compared to Kymera Therapeutics' net margin of -285.33%. CareDx's return on equity of 2.87% beat Kymera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-285.33%	-21.22%	-19.21%
CareDx	24.23%	2.87%	2.17%

CareDx has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	230.26	-$311.35M	-$3.24	N/A
CareDx	$379.80M	6.41	-$21.35M	$2.07	22.74

Summary

CareDx beats Kymera Therapeutics on 10 of the 15 factors compared between the two stocks.

Get CareDx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CDNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CDNA vs. The Competition

Export

Metric	CareDx	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.43B	$3.72B	$7.06B	$12.95B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	22.74	9.13	269.75	24.74
Price / Sales	6.41	1,274.20	652.34	108.60
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	7.99	17.66	11.27	6.42
Net Income	-$21.35M	-$13.25M	$3.45B	$347.12M
7 Day Performance	-1.63%	5.36%	3.56%	2.48%
1 Month Performance	65.10%	-1.74%	-0.58%	-1.04%
1 Year Performance	293.23%	61.36%	77.52%	23.22%

CareDx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CDNA CareDx	3.2712 of 5 stars	$47.07 +0.8%	$47.75 +1.4%	+290.1%	$2.43B	$379.80M	22.74	740
PTGX Protagonist Therapeutics	1.4765 of 5 stars	$132.28 -3.2%	$123.00 -7.0%	+185.6%	$8.79B	$46.02M	N/A	120	Earnings Report Analyst Downgrade Analyst Revision Gap Up
SYRE Spyre Therapeutics	2.2588 of 5 stars	$94.93 -3.5%	$101.42 +6.8%	+592.0%	$8.65B	$890K	N/A	73	Earnings Report Analyst Upgrade
IONS Ionis Pharmaceuticals	3.7353 of 5 stars	$54.49 +5.3%	$94.65 +73.7%	+35.8%	$8.60B	$874.09M	N/A	1,402
PRAX Praxis Precision Medicines	3.8121 of 5 stars	$305.51 -0.8%	$563.50 +84.4%	+685.3%	$8.58B	$8.55M	N/A	110	Positive News Earnings Report Analyst Forecast Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CDNA) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CareDx (CDNA) Competitors

CDNA vs. PTGX, SYRE, IONS, PRAX, and KYMR

How does CareDx compare to Protagonist Therapeutics?

Summary

How does CareDx compare to Spyre Therapeutics?

Summary

How does CareDx compare to Ionis Pharmaceuticals?

Summary

How does CareDx compare to Praxis Precision Medicines?

Summary

How does CareDx compare to Kymera Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDNA vs. The Competition

CareDx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CareDx (CDNA) Competitors

CDNA vs. PTGX, SYRE, IONS, PRAX, and KYMR

How does CareDx compare to Protagonist Therapeutics?

Is PTGX or CDNA more profitable?

Do analysts rate PTGX or CDNA?

Does the media refer more to PTGX or CDNA?

Do institutionals and insiders believe in PTGX or CDNA?

Which has more volatility and risk, PTGX or CDNA?

Which has stronger valuation and earnings, PTGX or CDNA?

Summary

How does CareDx compare to Spyre Therapeutics?

Does the media favor CDNA or SYRE?

Do analysts prefer CDNA or SYRE?

Is CDNA or SYRE more profitable?

Which has more volatility and risk, CDNA or SYRE?

Which has higher valuation and earnings, CDNA or SYRE?

Do insiders & institutionals have more ownership in CDNA or SYRE?

Summary

How does CareDx compare to Ionis Pharmaceuticals?

Do analysts recommend CDNA or IONS?

Is CDNA or IONS more profitable?

Do insiders and institutionals hold more shares of CDNA or IONS?

Which has better valuation & earnings, CDNA or IONS?

Does the media favor CDNA or IONS?

Which has more volatility and risk, CDNA or IONS?

Summary

How does CareDx compare to Praxis Precision Medicines?

Is PRAX or CDNA more profitable?

Which has stronger earnings and valuation, PRAX or CDNA?

Which has more volatility and risk, PRAX or CDNA?

Do insiders & institutionals believe in PRAX or CDNA?

Does the media refer more to PRAX or CDNA?

Do analysts rate PRAX or CDNA?

Summary

How does CareDx compare to Kymera Therapeutics?

Do analysts rate KYMR or CDNA?

Which has more volatility & risk, KYMR or CDNA?

Does the media prefer KYMR or CDNA?

Is KYMR or CDNA more profitable?

Which has higher earnings and valuation, KYMR or CDNA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDNA vs. The Competition

CareDx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools